S100 calcium-binding protein A1 (S100A1)

S100 calcium-binding protein A1 (S100A1) is a small EF-hand calcium-sensing protein primarily expressed in the myocardium and skeletal muscle, where it acts as a critical regulator of calcium homeostasis and contractile performance. Upon binding calcium, S100A1 undergoes a conformational change that allows it to interact with and modulate several key proteins, including ryanodine receptors (RyR1 and RyR2), the sarcoplasmic reticulum Ca2+-ATPase (SERCA2a), and various enzymes and transcription factors. In the heart, S100A1 levels are significantly downregulated during the progression of chronic heart failure, leading to impaired calcium handling and reduced systolic and diastolic function. Restoring S100A1 levels via gene therapy has shown therapeutic promise in enhancing cardiac output and improving survival in preclinical models. Conversely, S100A1 is often upregulated in certain cancers, such as melanoma and papillary thyroid carcinoma, where it can promote tumor cell proliferation and metastasis, making it a potential target for small-molecule inhibitors. Beyond its intracellular roles, extracellularly released S100A1 can act as a damage-associated molecular pattern (DAMP) or exert protective effects on cardiomyocytes, suggesting a complex role as both a diagnostic biomarker and a therapeutic target.

Other names

Protein S100-A1S100-alphaS100AS100

Drugs targeting S100A1 function through several modalities: gene therapy aims to restore physiological protein levels in the heart to normalize calcium handling and contractility; small molecule antagonists competitively bind to the hydrophobic cleft exposed by calcium to inhibit interactions with oncogenic targets in cancer; and certain agents modulate S100A1's regulatory effects on the RyR2 and SERCA2a/phospholamban complex to enhance calcium sensitivity.